J9217 HCPCS code: Leuprolide acetate (for depot suspension), 7.5 mg

J9217 is the HCPCS Level II code for leuprolide acetate (for depot suspension), 7.5 mg. In 2024 Medicare paid an average of $138.12 per service for J9217 across 687,219 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 6 per day on outpatient hospital claims. Medicare volume fell 19% from 2022 to 2024 (848,352 to 687,219 services). In 2024, about 11,658 clinicians billed Medicare for J9217 for 84,011 beneficiaries; California, Florida, Texas accounted for 26% of services.

Code details

Who bills J9217 (2024)

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for J9217, 2022–2024

States with the most J9217 services (2024)

NCCI unit limits (MUE)

Medicare policy articles for this code

• A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Wellpoint Federal (MAC - Part A, MAC - Part B))
• A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Palmetto GBA (MAC - Part A, MAC - Part B))

Covered diagnoses (246 ICD-10-CM codes)

The diagnoses most often listed as covered in the policy articles above:

Showing 10 of 246. The full list, non-covered diagnoses and CSV export are in Caduvo.

What changed for J9217

• 1991-01-01: J9217 added to HCPCS Level II
• Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01

Frequently asked questions

What is HCPCS code J9217?

J9217 is the HCPCS Level II code for leuprolide acetate (for depot suspension), 7.5 mg. Short descriptor: "Leuprolide acetate suspnsion".

How much does Medicare pay for J9217?

In 2024, the average Medicare payment was $138.12 per service (average allowed $176.49).

Does Medicare cover J9217?

Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.

Which diagnoses support coverage for J9217?

Medicare policy articles that cite J9217 list 246 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include C08.0 (Malignant neoplasm of submandibular gland), C08.1 (Malignant neoplasm of sublingual gland), C48.1 (Malignant neoplasm of specified parts of peritoneum). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.

How many units of J9217 can be billed per day?

6 on outpatient hospital claims; 6 on practitioner claims (NCCI medically unlikely edits).

Related J92 codes

• J9200 — Injection, floxuridine, 500 mg
• J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
• J9202 — Goserelin acetate implant, per 3.6 mg
• J9203 — Injection, gemtuzumab ozogamicin, 0.1 mg
• J9204 — Injection, mogamulizumab-kpkc, 1 mg
• J9205 — Injection, irinotecan liposome, 1 mg
• J9206 — Injection, irinotecan, 20 mg
• J9207 — Injection, ixabepilone, 1 mg
• J9208 — Injection, ifosfamide, 1 gram
• J9209 — Injection, mesna, 200 mg
• J9210 — Injection, emapalumab-lzsg, 1 mg
• J9211 — Injection, idarubicin hydrochloride, 5 mg

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

• Run a reimbursement report for a device billed under J9217
• Watch J9217 for fee, coverage and descriptor changes
• Build a full Medicare revenue model for J9217

Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.

All J codes · HCPCS lookup